*Together with

(NASDAQ: HUGE)

Good day, 360 –

Here are our top investing ideas today – these setups look primed! Be the best prepared trader on the Street!

GFAI – Closed up over 43% after buyers return to artificial intelligence stocks

PLXP – Up over 100% this morning after Park West Asset Management LLC took a 4.9% stake in the company on Thursday

RLYB – Up over 24% in pre-market after Wedbush announced price target of $17

*A Message on Behalf of FSD Pharma

? Hot Stock of the Day ?

Biotech stocks are all the rage right now, and here is one you need to definitely look at right now – FSD Pharma (Nasdaq: HUGE).

One of the original Sharks? on Shark Tank, Kevin Harrington, just posted that he is excited to be working with FSD Pharma (Nasdaq: HUGE) on an upcoming “breakthrough new product” that could be an absolute gamechanger.

We are in the early stages of something that could be truly revolutionary right now. The stock is already up over 100% so far this year as investors are learning more about the opportunity at hand… and we could just be getting started!

A perfect “100% BUY” rating on Barchart just about says it all when it comes to the technicals for the price chart right now.

There is a lot to love about FSD Pharma (Nasdaq: HUGE) right now, so do your own homework on it, and see if this stock should have a place in your portfolio today!

*Sponsored by FSD Pharma. Please see disclosures below.

GFAI – Closed up over 43% after buyers return to artificial intelligence stocks

Artificial intelligence stocks got hit after Kerrisdale Capital issued a short report on C3.ai, ticker AI which had been the head of the snake of artificial intelligence plays. That sent the rest of the sector down with it.

However, after C3.ai (AI) issued a statement in regards to the short report, buyers returned to AI plays Thursday. Guardforce AI (GFAI) was the leader Thursday closing up over 43%. It’s gapping up another 23% in early morning trade from Thursday’s close.

$15.64 was Thursday’s high and should be an important level of potential support today.

Above it, potential targets to the upside are $18.79, $19.19, and $21, then $23.50 comes into play.

Below $15.64, there is potential support at $14, $13.50 and $12.70 with $12 below that. This move began around $9.

PLXP – Up over 100% this morning after Park West Asset Management LLC took a 4.9% stake in the company on Thursday

PLx Pharma (PLXP) traded on increased volume on Thursday, but the move didn’t come until after hours. Thursday pre-market the company reported that Park West Asset Management LLC had taken a 4.9% stake in the company.

There was not much price movement, but there was increased volume. It wasn’t until after-hours Thursday until the stock rocketed over 70%. This morning that strength has continued, with PLXP now up around 120% from Thursday’s close. The stock is trading around $0.25 in the pre-market. The stock was trading above $2 in 2022.

The $0.20 level was support in the pre-market and that should be a major level to watch today.

Above that, the first major target for bulls would be the pre-market high at $0.2905 although $0.26 is also a level of resistance. Above $0.2905 targets to the upside are $0.32, $0.35, $0.40, $0.46 and $0.50, with a gap to fill at $0.60.

Below $0.20, there is potential support at $0.16, $0.15, $0.12 and then a gap to fill at $0.1051.

RLYB – Up over 24% in pre-market after Wedbush announced price target of $17

Rallybio (RLYB) is trading higher this morning after Wedbush initiated coverage on the stock with an Outperform Rating and announced a $17 price target.

Last week RLYB announced clinical proof of concept results for RLYB 211 an Anti-HPA-1a Polyclonal Antibody for the prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) published in the Journal of Thrombosis and Haemostasis. It’s a rare bleeding disorder.

$5.21 was a support area in the pre-market and should be a major level to watch this morning.

Above it, targets to the upside are $5.47 and then the pre-market high of $6.14, with $6.50 and $7 above that.

Below $5.21 there is potential support at $5, with a gap to fill at $4.91 with $4.70 and $4.30 targets below that.

Economic Calendar (EST)

10:00am Wholesale Inventories

4:15pm Fed Speaker John Williams

Earnings for Today (After Market)

LVRO, PSMT, TLRY

Top Headlines

TSLA: Tesla opening Megapack factory in Shanghai to supplement output of Megapack factory in California — ELON MUSK TWEET

TSLA: Tesla is increasing production rapidly in Texas, California & Nevada. Our competitors require subsidies, not us. That said, if competitors get subsidies, Tesla should get them too. Tesla’s competitive position would improve if all subsidies ended. — ELON MUSK

BG Bunge to Acquire Louisiana State-of-the-Art Refinery from Fuji Oil Enhancing its Position in the Vegetable Oils Market

BORR Borr Drilling Limited – Announcement of new contract

INTC Intel leak has U.S. officials bracing for impact at home and abroad – Reuters

AAPL: IDC Reported Sunday: Apple Global PC Shipments Fell 40.5% In Q1 YoY; Dell Shipments Fell 31%

NIO: Nio Cuts Delivery Times Again While Tesla Model Y China Buyers Keep Waiting

LLY Eli Lilly warns EU will miss out on key drugs under new patent rules – FT

UBER – Emirates Telecom to buy 50% of Uber’s Careem super app

DRRX DURECT Announces Peer-Reviewed Article Accepted for Publication with Additional Data from Previously Completed Phase 2a Study of Larsucosterol in Alcohol-Associated Hepatitis

AULT: Ault Alliance Announces Special Dividend with a Record Date of April 20, 2023

PKX up pm on a recovery in steel demand and solid future growth in its battery-material business.

IMOS – ChipMOS March revenue improved for second straight month amid uptick in LCD drivers demand

LODE: Comstock Advances Asset and Facility Sales for $27 Million

IGT: IGT Signs Three-Year Sports Betting Contract Extension with Rhode Island Lottery

MNK Mallinckrodt to Present Data on TERLIVAZ(R) (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the National Kidney Foundation (NKF) 2023 Spring Clinical Meeting (SCM)

TLSA: Tiziana Life Sciences Announces Presentations on Intranasal Foralumab at the “Preserving the Brain” Scientific Conference and Exhibit at Prada Rong Zhai in Shanghai

CSIQ: Canadian Solar Unites Global Energy Development and Services Under Recurrent Energy Brand

CANF Can-Fite: EMA Gives Green Light for Piclidenoson Pivotal Phase III Clinical Trial for Psoriasis Treatment

AMPY: Amplify Energy Commences Restart Operations at Beta Field

FOCS Focus Financial Partners Announces Expiration of “Go-Shop” Period in Connection with its Acquisition by Clayton, Dubilier & Rice

AMZN Whole Foods Markets is exploring building off-site kitchens to supply food bars – WSJ

PRTK: Paratek Pharmaceuticals Presenting New Data from NUZYRA(R) (omadacycline) and Investigator-Initiated Research Programs at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) 2023

EQT: EQT And Wheeling Park Commission Launch Forestry Management Program at Oglebay

ABEO Abeona Therapeutics Announces Multiple Abstracts Accepted from its AAV Ophthalmology Program at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

BBBY Bed Bath & Beyond Inc. Addresses Important Information Ahead of Special Meeting of Shareholders on May 9, 2023, seeking holder approval for reverse stock split.

ENVX: Enovix Issues Purchase Orders for Agility Line and Completes Gen2 Autoline Equipment Orders

EWJ Japan’s new central bank chief vows to guide policy ‘flexibly’ Cnbc

MDU MDU Resources Announces Launch of Knife River Holding Company’s Notes Offering in Connection with Anticipated Knife River Spinoff

CUTR J. Daniel Plants and David Mowry Call for Special Stockholder Meeting to Reconstitute Cutera’s Board

VTOL Argus Research Initiates Equity Research Report Coverage on Bristow Group Inc. (NYSE:VTOL)

CANO Concerned Shareholders of Cano Health Issue Open Letter Regarding the Urgent Need for Leadership and Strategy Changes at the Company

Questions or concerns about our products? Email [email protected](C) Copyright 2022, RagingBull – Refund Policy – Privacy Policy – Terms & Conditions

*PAID ADVERTISEMENT. RagingBull has been paid fifteen thousand dollars by ach bank transfer by FSD Pharma for advertising from a period beginning on April 10 , 2023 through April 14 of the same year. As a result of this advertisement and other marketing efforts, Raging Bull may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of this advertisement, the owners of Raging Bull, do not hold a position in FSD Pharma. This advertisement and other marketing efforts may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of FSD Pharma, increased trading volume, and possibly an increased share price of the FSD Pharma securities, which may or may not be temporary and decrease once the marketing arrangement has ended.

FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. This advertisement is for educational and informational purposes only. All material information contained in this advertisement is based on information generally available to the public, which public information is believed to be reliable and accurate. Nevertheless, Raging Bull can guarantee the accuracy or completeness of the information. This advertisement does not purport to be a complete analysis of any company’s financial position. This advertisement or any statements made in it is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular individual. The statements made in this advertisement should NOT be relied upon for purposes of investing in the companies mentioned in this advertisement, nor should they be construed as a personalized recommendation to you to buy, sell, or hold any position in any security mentioned in this advertisement or in any other security or strategy. It is strongly recommended that you consult a licensed or registered professional before making any investment decision.

SUBSTANTIAL RISK INVOLVED. Any individual who chooses to invest in any securities of the companies mentioned in this advertisement should do so with caution. Investing or transacting in any securities involves substantial risk; you may lose some, all, or possibly more than your original investment. Readers of this advertisement bear responsibility for their own investment research and decisions, and should use information from this advertisement only as a starting point for doing additional independent research in order to allow individuals to form their own opinion regarding investments. It is easy to lose money investing or trading, and we recommend always seeking individual advice from a licensed or registered professional and educating yourself as much as possible before considering any investments.

Our reports/releases are a commercial advertisement and are for general information purposes ONLY. A portion of our business is engaged in the marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use. A portion of RagingBull’s business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our websites, email, SMS, push notifications. This compensation is a major conflict of interest in our ability to provide unbiased reporting. Therefore, this communication should be viewed as a commercial advertisement only. Note, we periodically conduct interviews and issue stock alerts that we are not compensated for. These are purely for the purpose of company awareness, and to generate subscription revenues. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Frequently, companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the corporate awareness program ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct.

NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Raging Bull, or any of their owners, employees or independent contractors is currently registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization.

WE MAY HOLD SECURITIES DISCUSSED. Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication.

TRADEMARKS. All trademarks used in this advertisement are the property of their respective trademark holders and no endorsement by such owners of the contents of the advertisement is made or implied.